Natalizumab (Tysabri) prior authorization at Centene
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Centene requires prior-authorization documentation for Natalizumab (Tysabri): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 60 days to appeal.
The PA criteria you'll need to meet
Centene reviews Natalizumab (Tysabri) prior authorizations against its medical policy . Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Centene's medical policy URL referenced in the cover letter
Centene's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Marketplace network adequacy issues
- Medicaid step therapy
- Specialty drug exclusions
Natalizumab (Tysabri)-specific denial patterns and context
Across payers (not just Centene), Natalizumab (Tysabri)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- JC virus antibody index threshold restrictions
- Step therapy requiring oral DMT first
- Plan-mandated biosimilar switch (Tyruko approved 2023)
- Site-of-care reduction
Brand: Tysabri. α4-integrin antagonist for relapsing MS. REMS-restricted (TOUCH program) due to PML risk. Biosimilar Tyruko (natalizumab-sztn) FDA-approved August 2023 — plans now mandating switch.
Manufacturer patient-assistance program: Biogen Support Services — relevant when a Centene denial sticks and the patient needs bridge access while appealing.
How Centene approaches Biologic drugs (mAbs and biosimilars) PAs
Centene's Biologic drugs (mAbs and biosimilars) reviewer typically anchors Natalizumab prior-auth decisions on medicaid step therapy and specialty drug exclusions. Pharmacy-benefit review for Natalizumab at Centene is routed through Envolve Pharmacy Solutions / state-specific Medicaid PBMs. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 60-day internal-appeal window begins from the denial date. Centene's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Centene is domiciled in MO, so unresolved appeals escalate to the MO insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Largest Medicaid MCO in US.
If the PA is denied
Centene gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://ambetterhealth.com/provider-resources) with the same packet plus a peer-reviewed citation supporting Natalizumab (Tysabri)for the patient's indication.
Medicare Advantage path: if Centene misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.
Centene as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. For Natalizumab, the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Centene denial on DenialHelp.
Contact Centene
- Provider portal: https://ambetterhealth.com/provider-resources
Frequently asked questions
What documentation does Centene need for Natalizumab (Tysabri) prior auth?
Centene's typical PA packet for Natalizumab (Tysabri): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Centene?
Standard Natalizumab (Tysabri) PA decisions at Centene: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136. Medicare Advantage adds the 14-day extension rule under 42 CFR Part 422.
What does Centene most often reject Natalizumab (Tysabri) for?
Across Centene's book the common rejection patterns include: Marketplace network adequacy issues; Medicaid step therapy; Specialty drug exclusions. For Natalizumab (Tysabri) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Centene typically require before approving Natalizumab?
Centene's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For Natalizumab, attach the specific disease-activity instrument Centene accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Envolve Pharmacy Solutions / state-specific Medicaid PBMs. External-review escalation for Centene fully-insured policies sits with the MO insurance department.
How do I prep for a peer-to-peer with Centene on Natalizumab (Tysabri)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Natalizumab (Tysabri) PA packet
Open ApprovalHelp — generate a Natalizumab (Tysabri) prior-auth packet tailored to Centene's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com